BG
CARM

BlackRock Group’s Carisma Therapeutics CARM Stock Holding History

BlackRock Group’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,439
Closed -$81K – 3052
2015
Q2 		$81K Buy
1,439
+1,355
+1,613% +$191K ﹤0.01% 2802
2015
Q1 		$15K Buy
+84
New +$18.4K ﹤0.01% 2825
2014
Q2 		– Sell
-1,840
Closed -$597K – 2825
2014
Q1 		$597K Buy
+1,840
New +$551K ﹤0.01% 2184

Other funds holding CARM

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Rotella Capital Management Bellevue, Washington $1.47M AUM 12.32% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's CARM Position: Q3 2015 in Review

BlackRock Group sold out of Carisma Therapeutics (CARM) in Q3 2015, closing a stake of 1,439 shares — an estimated $81K sold.

BlackRock Group first reported a position in CARM in Q1 2014 and held it in 3 quarters. The position peaked at $597K in Q1 2014. 30 funds tracked by Wall St. Rank hold CARM as of Q3 2015.

  • BlackRock Group reported no remaining Carisma Therapeutics position as of Q3 2015 after selling out during the quarter.
  • BlackRock Group sold 1,439 Carisma Therapeutics shares in Q3 2015, an estimated $81K.
  • BlackRock Group first reported a position in Carisma Therapeutics in Q1 2014 and held it in 3 quarters.
  • BlackRock Group's Carisma Therapeutics position peaked at $597K in Q1 2014.
  • 30 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2015.

Based on BlackRock Group's 13F filing for Q3 2015, filed 13 Nov 2015.